评估SpeeDx ResistancePlus GC与GC 23S 2611 (beta)分子检测对淋球菌环丙沙星和阿奇霉素耐药/敏感的预测
该研究评估了两种SpeeDx分子检测(ResistancePlus GC和GC 23S 2611 beta)预测淋球菌对环丙沙星和阿奇霉素耐药/敏感的性能。ResistancePlus GC检测淋球菌及环丙沙星耐药性能良好,而GC 23S 2611 beta预测阿奇霉素耐药敏感性不足。
要点
- ResistancePlus GC预测环丙沙星耐药敏感性99.8%、特异性99.8%。
- GC 23S 2611 beta预测阿奇霉素耐药敏感性仅64.3%。
- 两检测与非淋球菌奈瑟菌有交叉反应,软件可解决大部分。
核心结论
- ResistancePlus GC检测淋球菌及环丙沙星耐药性能良好,GC 23S 2611 beta预测阿奇霉素耐药敏感性欠佳。
主要发现
- ResistancePlus GC在AC2样本中检测淋球菌敏感性98.6%、特异性100%。
- ResistancePlus GC检测GyrA S91 WT/S91F敏感性100%、特异性100%,预测环丙沙星表型耐药敏感性99.8%、特异性99.8%。
- GC 23S 2611 beta在AC2样本中检测淋球菌敏感性95.8%、特异性100%。
- GC 23S 2611 beta检测23S rRNA C2611 WT/C2611T敏感性100%、特异性99.9%,预测阿奇霉素表型耐药敏感性64.3%、特异性99.9%。
- 两检测与非淋球菌奈瑟菌有交叉反应,分析软件解决了大部分交叉反应。
关键数值与推荐
- ResistancePlus GC检测淋球菌敏感性98.6%、特异性100%;预测环丙沙星耐药敏感性99.8%、特异性99.8%。
- GC 23S 2611 beta检测淋球菌敏感性95.8%、特异性100%;预测阿奇霉素耐药敏感性64.3%、特异性99.9%。
临床怎么用
- ResistancePlus GC可用于泌尿生殖道样本淋球菌检测及环丙沙星耐药预测。
- GC 23S 2611 beta预测阿奇霉素耐药敏感性不足,需优化并纳入其他大环内酯耐药决定簇。
局限性
- GC 23S 2611 beta预测阿奇霉素耐药敏感性不理想。
- 两检测与非淋球菌奈瑟菌存在交叉反应,虽多数由软件解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate molecular assays for prediction of antimicrobial resistance (AMR)/susceptibility in Neisseria gonorrhoeae (Ng) can offer individualized treatment of gonorrhoea and enhanced AMR surveillance. OBJECTIVES: We evaluated the new ResistancePlus® GC assay and the GC 23S 2611 (beta) assay (SpeeDx), for prediction of resistance/susceptibility to ciprofloxacin and azithromycin, respectively. METHODS: Nine hundred and sixty-seven whole-genome-sequenced Ng isolates from 20 European countries, 143 Ng-positive (37 with paired Ng isolates) and 167 Ng-negative clinical Aptima Combo 2 (AC2) samples, and 143 non-gonococcal Neisseria isolates and closely related species were examined with both SpeeDx assays. RESULTS: The sensitivity and specificity of the ResistancePlus® GC assay to detect Ng in AC2 samples were 98.6% and 100%, respectively. ResistancePlus® GC showed 100% sensitivity and specificity for GyrA S91 WT/S91F detection and 99.8% sensitivity and specificity in predicting phenotypic ciprofloxacin resistance. The sensitivity and specificity of the GC 23S 2611 (beta) assay for Ng detection in AC2 samples were 95.8% and 100%, respectively. GC 23S 2611 (beta) showed 100% sensitivity and 99.9% specificity for 23S rRNA C2611 WT/C2611T detection and 64.3% sensitivity and 99.9% specificity for predicting phenotypic azithromycin resistance. Cross-reactions with non-gonococcal Neisseria species were observed with both assays, but the analysis software solved most cross-reactions. CONCLUSIONS: The new SpeeDx ResistancePlus® GC assay performed well in the detection of Ng and AMR determinants, especially in urogenital samples. The GC 23S 2611 (beta) assay performed relatively well, but its sensitivity, especially for predicting phenotypic azithromycin resistance, was suboptimal and further optimizations are required, including detection of additional macrolide resistance determinant(s).
引用
- Hadad R, Cole MJ, Ebeyan S, et al. Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae. J Antimicrob Chemother. 2021. PMID: 32929456. doi:10.1093/jac/dkaa381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。